About Bio-Gene
Bio-Gene is a company based in Melbourne (Australia) founded in 1995.. Bio-Gene has raised $4.05 million across 7 funding rounds from investors including U.S. Department of Defense. Bio-Gene offers products and services including Flavocide and Qcide. Bio-Gene operates in a competitive market with competitors including UPL, Terramera, MoA Technology, Vestaron and Micropep, among others.
- Headquarter Melbourne, Australia
- Stage Public
-
Sectors
Chemicals & MaterialsAgriculture
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Bio-Gene Technology Ltd
-
Annual Revenue
$0 (USD)-100as on Jun 30, 2025
-
Net Profit
$-1.7 M (USD)-7.28as on Jun 30, 2025
-
EBITDA
$-2.03 M (USD)-0.15as on Jun 30, 2025
-
Total Equity Funding
$4.05 M (USD)
in 7 rounds
-
Latest Funding Round
$2.1 M (USD), Post-IPO
May 05, 2025
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bio-Gene
Bio-Gene is a publicly listed company on the ASX with ticker symbol BGT in Australia, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Bio-Gene
Bio-Gene offers a comprehensive portfolio of products and services, including Flavocide and Qcide. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Synthetic molecule for controlling insect pests in crops and storage.
Natural oil product for safe pest management in various applications.
Funding Insights of Bio-Gene
Bio-Gene has successfully raised a total of $4.05M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.1 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $2.1M
-
First Round
First Round
(01 Mar 2016)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Post-IPO - Bio-Gene | Valuation |
investors |
|
| Jan, 2025 | Amount | Grant - Bio-Gene | Valuation |
investors |
|
| Nov, 2023 | Amount | Post-IPO - Bio-Gene | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Bio-Gene
Bio-Gene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include U.S. Department of Defense. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Military forces are provided by the U.S. Department of Defense for national security.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Bio-Gene
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Bio-Gene
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Bio-Gene Comparisons
Competitors of Bio-Gene
Bio-Gene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as UPL, Terramera, MoA Technology, Vestaron and Micropep, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Sustainable agriculture technologies and solutions are provided to farmers globally.
|
|
| domain | founded_year | HQ Location |
Plant-based biopesticides are developed for agricultural applications by Terramera.
|
|
| domain | founded_year | HQ Location |
Plant-based biologicals for weed control in agriculture are developed.
|
|
| domain | founded_year | HQ Location |
Biological insecticides and pesticides are developed from spider peptides.
|
|
| domain | founded_year | HQ Location |
Plant-based crop protection products are developed for targeted agricultural applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Bio-Gene
Frequently Asked Questions about Bio-Gene
When was Bio-Gene founded?
Bio-Gene was founded in 1995 and raised its 1st funding round 21 years after it was founded.
Where is Bio-Gene located?
Bio-Gene is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Who is the current CEO of Bio-Gene?
Tim Grogan is the current CEO of Bio-Gene.
Is Bio-Gene a funded company?
Bio-Gene is a funded company, having raised a total of $4.05M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $1.27M, raised on Mar 01, 2016.
What does Bio-Gene do?
Developing a patent protected product platform as a new class of insecticides. The company is developing two products Qcide and Flavocide. Qcide is developed from oil extracts of Gympie Messmate and is focused on organic insect control and Flavocide is a chemically synthesized product developed as a natural identical molecule to molecules also found in Eucalyptus cloeziana extracts. The company uses beta-triketones to address the problem of insecticide resistance and toxicity. It also owns patents covering the use of beta-triketone insecticides for insect control.
Who are the top competitors of Bio-Gene?
Bio-Gene's top competitors include Terramera, Vestaron and MoA Technology.
What products or services does Bio-Gene offer?
Bio-Gene offers Flavocide and Qcide.
Is Bio-Gene publicly traded?
Yes, Bio-Gene is publicly traded on ASX under the ticker symbol BGT.
Who are Bio-Gene's investors?
Bio-Gene has 1 investor. Key investors include U.S. Department of Defense.
What is Bio-Gene's ticker symbol?
The ticker symbol of Bio-Gene is BGT on ASX.